Skip to content

Advanced bladder cancer: stages and treatment

What advanced means, the stages, the tests and the treatment, whether aimed at cure or at controlling the disease.

Dr. Petronio Melo, urologistA reference in robotic surgery for kidney and bladder tumors
CRM-SP 157.598 · RQE 70.275
Reviewed by Dr. Petronio Melo on November 20, 2026
Book a consultation
Drawing of the bladder from the front, in cross-section, with the prostate below and a purple tumor that crosses the whole wall and reaches the fat outside. On both sides, the pelvic arteries and veins with lymph nodes, two of them enlarged and purple, on the side of the tumor
On this page

Quick answer

Advanced bladder cancer is cancer that has grown into the bladder muscle or beyond it, into the surrounding fat, nearby organs, lymph nodes or other parts of the body.1 When there are no distant metastases, treatment aims at cure: chemotherapy first and then radical cystectomy, or bladder-sparing treatment in selected cases.3 When there are metastases, the European guideline recommends starting with enfortumab vedotin plus pembrolizumab for those who can receive it, together with care that relieves symptoms.4 In my practice, I perform cystectomy with an ileal conduit (Bricker) in most cases, and the hospital stay is about 1 week on average.

What advanced means

The line that separates cases is the muscle of the bladder wall. Most tumors stay in the inner lining and are treated through the urethra, as I explain in is a bladder tumor serious?. When the tumor reaches the muscle, the cancer is called muscle-invasive, and the treatment changes.

The stages follow the TNM classification, in the 2025 edition used by the European guideline. T says how far the tumor has grown, N refers to the lymph nodes and M to distant metastases:1

StageWhat it means
T2The tumor invades the muscle: T2a in the inner half, T2b in the outer half1
T3It grows into the fat around the bladder: T3a only under the microscope, T3b as a visible mass1
T4T4a reaches the prostate, seminal vesicles, uterus or vagina; T4b, the pelvic or abdominal wall1
N1 to N3Affected lymph nodes: N1, one pelvic node; N2, several; N3, the common iliac nodes1
M1M1a, lymph nodes outside the pelvis; M1b, other distant metastases1

In practice, treatment falls into two groups: disease still within the pelvis, treated with curative intent, and disease with distant metastases, treated with medication.3,4

Symptoms

The most common sign of bladder cancer is blood in the urine, often without pain. In advanced disease, there may also be difficulty passing urine, pain in the lower back on one side, loss of appetite and weight, tiredness, swollen feet and bone pain.6

These symptoms also occur in conditions unrelated to cancer. Anyone with blood in the urine should see a urologist, even if it happened only once. The page on blood in the urine explains the work-up.

Tests to find the stage

The diagnosis comes from TURBT, which removes the tumor through the urethra and shows in the report whether it invades the muscle. Then imaging shows how far the disease has spread:2

  • CT of the chest, abdomen and pelvis: the European guideline recommends it for muscle-invasive cancer, with phases that also show the kidneys and ureters.2
  • Bladder MRI: it can help tell a tumor in the layer beneath the lining from one that has invaded the muscle. When it is used for this, it should be done before TURBT.2
  • FDG PET-CT: it can add information, especially about the lymph nodes.2
  • Bone scan and brain imaging: not done routinely, only when symptoms or signs raise suspicion.2

Treatment aimed at cure

When the cancer invades the muscle and there are no distant metastases, the curative options in the European guideline are radical cystectomy and bladder-sparing treatment.3

Chemotherapy before surgery. In an analysis of 11 trials with 3,005 patients, platinum-based chemotherapy before surgery improved 5-year survival by 5 percentage points.7 In an American trial of 317 patients, more men and women reached surgery with no tumor left after chemotherapy first, 38% against 15%.8 For those who can receive cisplatin, the European guideline recommends cisplatin and gemcitabine chemotherapy together with durvalumab, an immunotherapy.3 In the NIAGARA trial, 2-year survival was 82.2% with durvalumab and 75.2% without it.9 For those who cannot receive cisplatin, the guideline recommends enfortumab vedotin plus pembrolizumab before and after surgery.3 In my practice, following the protocols, the great majority of patients receive chemotherapy before surgery.

Radical cystectomy. Cystectomy removes the bladder and the pelvic lymph nodes; in men, the prostate comes out too. The European guideline recommends surgery for T2 to T4a tumors without suspicious lymph nodes and asks that it not be delayed by more than 3 months, except in patients receiving chemotherapy first.3 Afterwards, urine is given a new path, usually built from a piece of bowel. For patients whose post-surgery report shows high risk and who cannot have or decline cisplatin chemotherapy, the guideline recommends immunotherapy with nivolumab.3

Bladder-sparing treatment. It combines the most complete removal of the tumor through the urethra, chemotherapy and radiotherapy. The European guideline offers it alongside cystectomy for a single tumor, T2 to T3a, without extensive carcinoma in situ, with at most one swollen kidney and with good bladder function.3 In a trial of 360 patients, adding chemotherapy to radiotherapy improved cancer control in the pelvis at 2 years, from 54% to 67%.10 In a North American study of 722 patients who could have had either treatment, 5-year metastasis-free survival was 74% with cystectomy and 75% with bladder preservation, and 13% of those who kept the bladder later needed it removed.11 Anyone who keeps the bladder needs follow-up with cystoscopy.3 In my practice, I offer bladder-sparing treatment, and the decision is shared with the patient.

When there are metastases

When the cancer has spread far, treatment is with medication, managed by the medical oncologist, and aims to control the disease and the symptoms. The European guideline recommends starting with enfortumab vedotin plus pembrolizumab for those who can receive it.4 In the EV-302 trial, with 886 patients, this combination was compared with platinum-based chemotherapy:12

OutcomeEnfortumab vedotin plus pembrolizumabChemotherapy
Median time without the disease progressing12.5 months6.3 months12
Median survival31.5 months16.1 months12
Serious side effects55.9%69.5%12

Median means that half of the patients were above that time and half below. These are figures for a group and do not say what will happen to each person.

Those who cannot receive this combination have other options in the guideline: platinum chemotherapy followed by avelumab maintenance, or cisplatin and gemcitabine with nivolumab. When the disease progresses, other drugs come in, such as erdafitinib for tumors with an FGFR gene alteration.4 For bone metastases, zoledronic acid or denosumab reduce bone complications.4

In American data from the SEER program, from 2016 to 2022, 5-year relative survival was 42% when the cancer had reached lymph nodes or nearby organs and 10% when it had spread far.14 These data predate the newest combination and are averages of many people, which do not say what will happen to each one.

Supportive and palliative care

In advanced disease, controlling symptoms is part of treatment from the start. The American oncology guideline recommends that people with advanced cancer receive palliative care early, at the same time as cancer treatment, and that the family receive this support too.13

The European guideline describes the most common forms of relief:5

  • Bleeding: radiotherapy helps stop bladder bleeding and, in an older study, controlled blood in the urine in 59% of patients. Removing the bladder is a last resort.5
  • Pain: radiotherapy also controls pain, in 73% of patients in the same study.5
  • Blocked urine flow: when the tumor blocks the kidney's outlet, a tube through the back (nephrostomy) or a tube inside the ureter (a stent) lets urine pass.5

In advanced disease, the choice also depends on what the patient wants for his or her life. This conversation is held calmly, with the patient and, if they wish, with the family.

How I approach it

At the consultation, I review the TURBT report and the imaging and explain the stage of the cancer. When cystectomy is indicated, I explain the ways of rebuilding the urinary path and what changes in daily life with each one. In my practice, I perform an ileal conduit (Bricker) in most cases, but the choice is made case by case with the patient, and the hospital stay is about 1 week on average. Following the protocols, the great majority of patients receive chemotherapy before cystectomy. I also offer bladder-sparing treatment, and the decision is shared.

I treat bladder cancer in São Paulo, from TURBT to robotic cystectomy. I have performed more than 1,500 robotic and laparoscopic operations, more than 500 of them robotic, and I operate with the da Vinci X and da Vinci Xi platforms. The decision is made together with the patient, and the family takes part if the patient wishes. The page robotic cystectomy: cost and insurance explains what is usually covered.

When to see a urologist

  • If TURBT showed cancer that invades the muscle
  • If you have bladder cancer and want another opinion on surgery or on keeping the bladder
  • If you see blood in your urine, even once
  • If clots appear or you cannot pass urine, get in touch the same day

Send your case

If you have been diagnosed with muscle-invasive bladder cancer and would like to know, before a consultation, whether robotic radical cystectomy makes sense for you, fill in the form below. It goes to my office, and you will get a reply within 24 hours by email or WhatsApp. The form does not replace a consultation: it helps plan the next step.

Frequently asked questions

What is advanced bladder cancer?

It is cancer that has grown into the bladder muscle or beyond it. In the TNM classification used by the European guideline, a tumor that reaches the muscle is T2, one that grows into the surrounding fat is T3 and one that reaches nearby organs or the pelvic wall is T4. Affected lymph nodes are N1 to N3, and distant metastasis is M1.1

Can advanced bladder cancer be cured?

When the cancer invades the muscle and has not spread far, treatment aims at cure: chemotherapy first, then radical cystectomy or bladder-sparing treatment.3 When there are metastases, drug treatment aims to control the disease and the symptoms. With enfortumab vedotin plus pembrolizumab, median survival was 31.5 months, compared with 16.1 months with chemotherapy.12

What does end-stage bladder cancer mean?

It is a common name for advanced disease that has spread to other organs. Even at this stage, there is drug treatment to control the cancer, and radiotherapy and other procedures to relieve bleeding, pain and blocked urine flow.4,5 The American oncology guideline recommends early palliative care alongside cancer treatment.13

What are the symptoms of advanced bladder cancer?

Besides blood in the urine, there may be difficulty passing urine, pain in the lower back on one side, loss of appetite and weight, tiredness, swollen feet and bone pain.6 These symptoms also occur in other conditions, and only an assessment shows the cause.

Why have chemotherapy before surgery?

Because it improves survival. In an analysis of 11 trials with 3,005 patients, platinum-based chemotherapy before surgery improved 5-year survival by 5 percentage points.7 The European guideline recommends cisplatin-based chemotherapy, now combined with durvalumab, for those who can receive it.3 In my practice, following the protocols, the great majority of patients receive chemotherapy before surgery.

Can it be treated without removing the bladder?

In selected cases, yes. Bladder-sparing treatment combines the most complete removal of the tumor through the urethra, chemotherapy and radiotherapy. The European guideline places it alongside cystectomy as a curative option for a single tumor, T2 to T3a, without extensive carcinoma in situ and with good bladder function.3 In a study of patients who could have had either treatment, cancer control at 5 years was similar.11 In my practice, I offer bladder-sparing treatment, and the decision is shared with the patient.

How long is the hospital stay after cystectomy?

In my practice, about 1 week on average. I perform an ileal conduit (Bricker) in most cases, and the type of reconstruction is chosen case by case with the patient.

References

  1. EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. European Association of Urology; 2026. Pathology and classification chapter (TNM 2025, 9th edition). EAU
  2. EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. European Association of Urology; 2026. Diagnostic evaluation chapter. EAU
  3. EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. European Association of Urology; 2026. Disease management chapter. EAU
  4. EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. European Association of Urology; 2026. Metastatic disease chapter. EAU
  5. EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. European Association of Urology; 2026. Quality of life and palliative care chapter. EAU
  6. American Cancer Society. Bladder Cancer Signs and Symptoms. Revised March 2024. American Cancer Society
  7. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur Urol. 2005;48(2):202-5. PubMed
  8. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859-66. PubMed
  9. Powles T, Catto JWF, Galsky MD, et al. Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer. N Engl J Med. 2024;391(19):1773-1786. PubMed
  10. James ND, Hussain SA, Hall E, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366(16):1477-88. PubMed
  11. Zlotta AR, Ballas LK, Niemierko A, et al. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis. Lancet Oncol. 2023;24(6):669-681. PubMed
  12. Powles T, Valderrama BP, Gupta S, et al. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N Engl J Med. 2024;390(10):875-888. PubMed
  13. Ferrell BR, Temel JS, Temin S, et al. Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017;35(1):96-112. PubMed
  14. National Cancer Institute. SEER Cancer Stat Facts: Bladder Cancer. Data from 2016 to 2022. NCI

Would you like to talk about your case?

In the consultation, I go over your tests and your priorities.

Book a consultation5.0186 Google reviews

Related guides